The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology, recommended by NICE.

Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.

Date Update 09 June 2025 The resolution start date for this topic has been delayed. The revised timeline for the evaluation will be available on the topic webpage in due course.

Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468] Technology appraisal guidance Venetoclax with ibrutinib for treating ...

There is a simple discount patient access scheme for nivolumab, and a patient access scheme plus commercial access agreement for ipilimumab. NHS organisations can get details on the Commercial Access ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

Programme director for Healthtech strategy and development. Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where innovative ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

NICE is unable to make a recommendation on tislelizumab (Tevimbra) for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy in adults. This is because ...

Somapacitan (Sogroya) is available on the NHS. It is a possible treatment for growth failure caused by growth hormone deficiency in people 3 to 17 years. Is this treatment right for me or my child?